VIVUS — Technical Presentation (December 2011)
13 slides from VIVUS's technical presentation, Dec 7, 2011
Slide 1: Weight Loss and Diabetic Status in Obese Diabetic Adults after 56 Weeks on PHEN/TPM CR
Nancy JV Bohannon, MD, FACP, FACE Director of Clinical Research, Cardiovascular Risk Reduction Program St Luke’s Hospital, San Francisco, CA, USA Wesley Day, PhD, Barbara Troupin, MD, MBA Weight Loss and Diabetic Status in Obese (BMI>35) Diabetic Adults after 56 Weeks on Phentermine/Topiramate CR (P
Slide 2: Author Disclosure
Author Disclosure Nancy Bohannon, MD Grant/Research Support: Calibra, Valeritas, Vivus Consultant/Advisory Board: Abbott, Biodel, Calibra, Halozyme, Johnson & Johnson, Lilly, Mannkind, Novartis, Roche, Santarus, Inc. Sanofi-Aventis, Tethys Bioscience, Valeritas, Vivus, Novo Nordisk, CeQur, Daiichi S
Slide 3: Background
Background Risk of developing diabetes increases with the length of time a patient has excess BMI1 The relative risk of diabetes increased 42 fold in men2 and 93 fold in women3 when BMIs increase from normal to obese with a BMI >35 We report here a potential pharmacotherapeutic approach to reduce we
Slide 4: The CONQUER Study
The CONQUER Study1 This presentation analyzed a subgroup of CONQUER patients with diabetes and a BMI >35 Population 18-70 years BMI ≥27 and ≤45 kg/m2 ≥2 obesity-related comorbid conditions: HTN, ↑triglycerides, pre-DM, T2DM, or waist circ >102 cm for and >88 cm for Study duration Titration over 4 we
Slide 5: Baseline Characteristics
Baseline Characteristics Placebo (n=58) PHEN/TPM CR 7.5/46 (n=24) PHEN/TPM CR 15/92 (n=65) Age (years) 52.5 (9.9) 51.9 (9.0) 51.4 (10.8) Women (%) 43 (74.1) 15 (62.5) 40 (61.5) Weight (kg)* 107.5 (13.1) 108.9 (11.2) 115.3 (17.0) BMI (kg/m2) 39.7 (2.9) 39.2 (2.8) 40.4 (3.0) Fasting glucose (mmol/L) 7
Slide 6: Weight Loss at Week (Completers on Study Drug)
Weight Loss at Week 56 (Completers on Study Drug) †P<0.05 vs placebo; ‡ P<0.0001 vs placebo Data represent LS mean± SEM ; *Calculated as (weight loss/excess weight) X 100. Ideal weight was determined based on a BMI of 25 kg/m2 and the subjects height at screening. Ideal weight (lb)=(25/703) X (heigh
Slide 7: Change in Glycaemic Parameters
Change in Glycaemic Parameters Fasting Glucose (mmol/L) Placebo (n=58) PHEN/TPM CR 7.5/46 (n=24) PHEN/TPM CR 15/92 (n=63) Baseline fasting glucose, mean (SD) 7.02 (1.6) 7.53 (2.0) 6.93 (1.6) LS mean change from baseline at 56 weeks 0.04 0.18 -0.65† Hemoglobin A1c (%) Placebo (n=58) PHEN/TPM CR 7.5/4
Slide 8: Correlation Between Percent Weight Loss and Improvement of Glycaemic Parameters
Correlation Between Percent Weight Loss and Improvement of Glycaemic Parameters Pearson Correlation Coefficients Fasting Glucose 0.475 (P < 0.0001) Fasting Insulin 0.253 (P = 0.0024) Hemoglobin A1c 0.504 (P < 0.0001)
Slide 9: Resolution of Diabetes
Resolution of Diabetes 1. Buchwald H, et al. JAMA 2004;292: 1724-1737. Resolution: percentage of patients with clinical and laboratory manifestations of diabetes resolved1 Off diabetes medications Normalized fasting blood glucose (<5.5 mmol/L) Chi –Square (7.1043) P=0.0287 The mean (SD) % hemoglobin
Slide 10: Adverse Events
Adverse Events AE (%) Placebo (n=58) PHEN/TPM CR 7.5/46 (n=24) PHEN/TPM CR 15/92 (n=65) Constipation 5.2 12.5 23.1 Upper respiratory tract infection 12.1 8.3 18.5 Paraesthesia 8.6 4.2 12.3 Insomnia 3.4 8.3 12.3 Dry mouth 3.4 8.3 10.8 Headache 6.9 0 10.8 Dysgeusia 0 4.2 9.2 Nasopharyngitis 12.1 12.5
Slide 11: PHEN/TPM CR in Context
PHEN/TPM CR in Context CONQUER (56 weeks) Placebo PHEN/TPM CR (N = 58) 7.5/46 (N = 24) 15/92 (N = 65) % Excess Weight Loss (% EWL) 7.4 17.8 32.6 1: J.D. Dixon & P.E. O’Brien. Diabetes Care 25: 358-363, 2002 n=50, EWL = 38% 2: G. Segato et al. Surg Obes Relat 4;(6): 132-7, 2010 n=52, EWL = 32% Does n
Slide 12: Summary
Summary Multiple options are needed to address the parallel diabetes and obesity epidemics. In this study, diabetics with a BMI > 35 treated with PHEN/TPM CR experienced: Improvements in glycaemic parameters Diabetic remission rate ≥15% with PHEN/TPM CR 15/92 33% EWL (12% weight loss) Weight loss wa
Slide 13: Conclusions
Conclusions PHEN/TPM CR could be a potential non-surgical approach for both treating obesity and improving glycaemic control in obese diabetic patients.